Cargando…

miR-34 – a microRNA replacement therapy is headed to the clinic

MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability a...

Descripción completa

Detalles Bibliográficos
Autor principal: Bader, Andreas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/
https://www.ncbi.nlm.nih.gov/pubmed/22783274
http://dx.doi.org/10.3389/fgene.2012.00120
_version_ 1782237117778231296
author Bader, Andreas G.
author_facet Bader, Andreas G.
author_sort Bader, Andreas G.
collection PubMed
description MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.
format Online
Article
Text
id pubmed-3387671
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33876712012-07-10 miR-34 – a microRNA replacement therapy is headed to the clinic Bader, Andreas G. Front Genet Genetics MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. Frontiers Research Foundation 2012-07-02 /pmc/articles/PMC3387671/ /pubmed/22783274 http://dx.doi.org/10.3389/fgene.2012.00120 Text en Copyright © Bader. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Genetics
Bader, Andreas G.
miR-34 – a microRNA replacement therapy is headed to the clinic
title miR-34 – a microRNA replacement therapy is headed to the clinic
title_full miR-34 – a microRNA replacement therapy is headed to the clinic
title_fullStr miR-34 – a microRNA replacement therapy is headed to the clinic
title_full_unstemmed miR-34 – a microRNA replacement therapy is headed to the clinic
title_short miR-34 – a microRNA replacement therapy is headed to the clinic
title_sort mir-34 – a microrna replacement therapy is headed to the clinic
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/
https://www.ncbi.nlm.nih.gov/pubmed/22783274
http://dx.doi.org/10.3389/fgene.2012.00120
work_keys_str_mv AT baderandreasg mir34amicrornareplacementtherapyisheadedtotheclinic